Navigation Links
BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
Date:10/25/2007

WOBURN, Mass., Oct. 25 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Jan van Heek, age 58, as Chairman of the Board of Directors.

Mr. van Heek is employed as a Senior Advisor to the CEO and the senior management team of Genzyme Corporation; he joined Genzyme in 1991 and has been responsible for building the Company's worldwide therapeutics, surgical and genetic testing businesses. He established Genzyme's European offices in the early 1990's before moving to the U.S. to head the Company's therapeutics division. Mr. van Heek has played a key role in building Genzyme's broad portfolio of businesses and manufacturing infrastructure worldwide. Prior to Genzyme, Mr. van Heek held various management positions at Baxter Healthcare Corporation in Europe and the U.S. At Baxter, his last position was as vice president/general manager of the global Fenwal Division of Baxter Healthcare Corporation based in Deerfield, Illinois. Mr. van Heek is a board member of Viacell Corporation, Zelos Corporation and PanGenetics BV. He received an M.B.A. from St. Gallen University, Switzerland and an executive degree from Stanford Business School, California.

Philip Astley-Sparke, President & CEO of BioVex Inc, said:

"Jan's appointment brings to the Board nearly two decades of experience in managing the commercial and manufacturing operations of one the world's preeminent biotechnology companies."

Jan van Heek, Chairman of BioVex Inc, said:

"I am excited to be joining BioVex at a transformational time in its development as it scales up its manufacturing operations to produce launch grade material. I look forward to working with the management team, the Board and the Company's investors in implementing the Company's substantial growth plans over the next year and beyond."

About BioVex

BioVex is a privately held bi
'/>"/>

SOURCE BioVex Inc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...sts of a two-dimensional carbon layer in which the... resembling a honeycomb. Carbon nanotubes are roll...ene sheets form graphite. Graphene boasts some ver...sistant, an excellent thermal conductor, and recon...d ductility. In addition, graphene is impermeable ...
(Date:11/23/2009)...UGA,ON,Nov.23/PRNewswire-FirstCall/-YMBioSciencesI...elopmentcompanythatidentifiesandadvancesadiversepo...tagesofdevelopment,todayreportedthatCytopia(ASX:CY...gCYT387,apotent,orally-administeredJAK1/JAK2inhibi...r,Minnesota.AproposaltomergeCytopiaintoYMhasbeenpr...
(Date:11/23/2009)... Contec’s Sporicidin disinfectant s...tal-grade disinfectants against H1N1 and Influenza...RWEB) November 24, 2009 -- Contec Inc, the leading...ced that their Sporicidin disinfectants have bee...enza A viruses, including Pandemic 2009 H1N1 influ...
(Date:11/23/2009)...BC,Nov.23/PRNewswire/-InimexPharmaceuticals,Inc.an...asitsPresidentandCEO. ,, Abramsbringsmorethan25...ex.Heisaco-inventorofthenuclearmedicineimagingagen...ey,plcwherehewasManager,BiomedicalResearchWorldwid...ey,BCandwasPresidentandCEOfrom1996to2006.AnorMEDdi...
Breaking Biology Technology:Polymer with honeycomb structure 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 2Inimex Announces Appointment of New CEO 2
...from MedImmune Inc., Elliott Sigal, M.D., Ph.D, fr..., Ph.D from the FDA, and Mark Ratne...IBC Life Sciences announced,the keynote line up fo...Innovative Therapeutics World Congress, to take pl...esentations will include speakers David M. Mott,fr...
...d Wednesday, May 7, 2008 at 10:00 AM EDT, CEDAR K...Nasdaq: EMIS ) today announced its financial resu...Emisphere will host a conference call to discuss f...y 7, 2008. A live Webcast of the conference,call c... http://www.emisphere.com .,The live conference ca...
..., Inc., a rapidly,growing medical device company d...surgical adhesives, announced today that it has cl...illion. The proceeds of this,transaction will supp...al,trials for its lead product, TissuGlu(R), a str...clinical development of Cohera,s product pipeline....
Other Biology Technology:Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBC's 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress 2Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 2Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 3Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 4Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 5Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 6Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results 7Cohera Medical, Inc. Announces Closing of Insider Round of Financing for Over $7.6 Million 2
(Date:11/23/2009)... is available in German . , Of all global c... in the atmosphere where it contributes to global ...d terrestrial ecosystems such as forests, grasslan... of aquatic and terrestrial ecosystems is consider...reducing climate change. However, new greenhouse g...
(Date:11/22/2009)...herited gene deletion can increase the likelihood ...splantation, an international team of researchers ... Nature Genetics . When the gene, called UGT2B17,... the recipient,s, transplants have a significantly...aft-versus-host disease, in which immune cells fro...
(Date:11/21/2009)...rmany, November 20,2009 / b3c newswire / - KINAX...f a financing round, gaining two new investors in ...e time KINAXO reports that Jrgen Schumacher has be...y board. , KINAXO shareholders Axel Ullrich, Hel...nys institutional investors Mountain Partners, Bio...
Breaking Biology News(10 mins):Intensive land management leaves Europe without carbon sinks 2Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 1Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 2Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 3American Chemical Societys Weekly PressPac June 3 2009 8740 1American Chemical Societys Weekly PressPac June 3 2009 8740 2American Chemical Societys Weekly PressPac June 3 2009 8740 3American Chemical Societys Weekly PressPac June 3 2009 8740 4American Chemical Societys Weekly PressPac June 3 2009 8740 5American Chemical Societys Weekly PressPac June 3 2009 8740 6American Chemical Societys Weekly PressPac June 3 2009 8740 7American Chemical Societys Weekly PressPac June 3 2009 8740 8American Chemical Societys Weekly PressPac June 3 2009 8740 9American Chemical Societys Weekly PressPac June 3 2009 8740 10Successful Disease Management Programs Can Play Role in Health Care Reform 48168 1Successful Disease Management Programs Can Play Role in Health Care Reform 48168 2Successful Disease Management Programs Can Play Role in Health Care Reform 48168 3Successful Disease Management Programs Can Play Role in Health Care Reform 48168 4Successful Disease Management Programs Can Play Role in Health Care Reform 48168 5Successful Disease Management Programs Can Play Role in Health Care Reform 48168 6
... Cincinnati (UC) scientists say that a recent scie...ant near Cincinnati has identified a second, poten...or former workers. , That sourcesix silos filled ... relatively high levels of radon exposure to 12 pe... of the workers were exposed to low levels of rado...
...ul antioxidant in green tea may prevent or delay t...orgia researchers say. , Researchers were testing...aboratory mouse with type 1 diabetes and primary S...g glands, causing dry mouth and eyes. , "Our stu... EGCG also can prevent and delay insulin-dependent...
...York, NY) The Parkinson,s Disease Foundation (PDF)...d investigations studying the potential of individ...ease (PD). , The grant will support the research ...M.D., Ph.D., both of the University of Wisconsin, ...ission to fund scientific research that has great ...
Other Biology News:Major source of radon exposure overlooked at former Ohio uranium-processing plant 2Major source of radon exposure overlooked at former Ohio uranium-processing plant 3Major source of radon exposure overlooked at former Ohio uranium-processing plant 4Green tea may delay onset of type 1 diabetes 2Green tea may delay onset of type 1 diabetes 3Parkinson's Disease Foundation announces award of $150,000 2
Acrylamide from Research Organics, Inc.
Acrylamide from Research Organics, Inc.
UltraPure Agarose from Invitrogen
Rabbit Anti-XTP4 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: